Our Partner

 
RJ
 
RJ

RJ Founded in 1929 in Spain, Reig Jofre is a leading industrial group in the European pharmaceutical market. Family owned, it has more than 600 employees and strong growth over the last years.

The structure includes four divisions: 

Industrial Services Division
The group is a leader in providing manufacturing services and out-licensing dossiers of specialised products. This activity is complemented with production services for third parties, specialising in sterile products for injection, freeze-dried products (with a dedicated center of excellence), and penicillin / cephalosporin antibiotics, as well as advanced topical formulations.

Pharma Division
RJ sells its own products in the Spanish market under the brands Reig Jofre, Medea, Orravan and Sala; and in the Nordics, under the brand Bioglan. Reig Jofre Group specialises in the fields of Dermatology, Women's Care, Respiratory, Anti-infectious, Pediatrics and Retail Consumer Healthcare products. In addition RJ is a key player in Spain and United Kingdom in the hospital sector, offering a wide range of injectable products.

R&D and Regulatory Division
The scientific division is dedicated to identifying and developing projects that are relevant for International markets. From improved formulation to new indications for existing molecules, as well as specialiced generics and molecular diagnostics. RJ has a wide experience in Decentralized and Mutual Recognition Procedures in Europe, as well as preparing FDA compliant Dossiers.

RJ Biotech Services
A multidisciplinary team with broad experience in the development of biological products, working closely with scientific knowledge, and translating the initial development into a robust and scalable process. RJ Biotech Services provides high quality development/optimization and GMP bioproduction services, with a special focus on injectableforms. We offer a wide range of services that cover the entire development chain (including analytical development, process development, quality control, quality assurance, stability studies and regulatory requirements).

 
(c) copy right, all rights recieved AUG PHARMA 2012,